FOLH1 and prostate cancer: A PSMA-PET scan revealed that the biopsy-confirmed locally advanced pancreatic cancer diagnosed three years prior harboured different metabolic expression compared to the metastatic lesions in the liver and bones, which were consistent with the separate pathology of prostate cancer (also subsequently biopsy proven).